Technology
Health
Biotechnology
Atara Biotherapeutics
$23.219876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$23.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.28 (-1.19%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ATRA and other stocks, options, ETFs, and crypto commission-free!
About
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. Read More The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
Employees
311
Headquarters
South San Francisco, California
Founded
2012
Market Cap
1.07B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
556.90K
High Today
$24.32
Low Today
$22.75
Open Price
$23.66
Volume
181.62K
52 Week High
$51.40
52 Week Low
$22.05
Collections
Technology
Health
Biotechnology
Medical
Therapy
2014 IPO
US
North America
News
Seeking AlphaMay 13
Atara Biotherapeutics: T-Cell Therapy Developer With Late-Stage Candidate In Rare Disease
Atara Biotherapeutics (ATRA) is an allogenic, off-the-shelf T-cell therapy developer with a late-stage pipeline targeting post-transplant lymphoproliferative disorder (EBV+PTLD) associated with Epstein-Barr Virus as its lead indication, with a slew of further indications backing it up.
Yahoo FinanceMay 9
Atara Biotherapeutics: 1Q Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $66.3 million in its first quarter. The South San Francisco, California-based company said it had a loss of $1.44 per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.48 per share. Atara Biotherapeutics shares have decreased slightly more than 1% since the beginning of the year. The stock has declined 13%...
Price Paid on Robinhood
28% Lower
Right Now
52 Week Low
$22.05
Average Price Paid
$32.08
52 Week High
$51.40
Earnings
-$1.75
-$1.47
-$1.20
-$0.92
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 31, Pre-Market